Big Sky Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2009



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Angiogenesis and Lymphangiogenesis in Cancer (A2)


Organizer(s) Lee M. Ellis and Luisa Iruela-Arispe
January 6—11, 2009
Big Sky Resort • Big Sky, Montana USA
Abstract Deadline: Sep 15, 2008
Late Abstract Deadline: Oct 9, 2008
Scholarship Deadline: Sep 15, 2008
Early Registration Deadline: Nov 6, 2008

Sponsored by Genentech BioOncology, ImClone Systems Corporation and sanofi-aventis

Summary of Meeting:
A concrete understanding of the mechanisms that regulate tumor angiogenesis has led to advances in the clinic; however multiple challenges remain. First, not all tumors or tumor types respond equally well to anti-VEGF therapy. And for those that do, many, if not all, eventually become refractory to anti-VEGF therapies. It is essential to understand the various factors that lead to the development and function of the neovascular network in tumors in order to improve therapies and identify predictive markers. In addition, understanding basic mechanisms of angiogenesis will lead to insights into other diseases where neovascularization is an important factor in the progression or resolution of the pathology. This symposium will provide a forum to discuss the current status of anti-angiogenic therapy, new insights into the molecular and morphologic abnormalities of the tumor vascular network, methods to investigate mechanisms of angiogenesis, the relationship of the tumor microenvironment to vascular and tumor stem cells, and elucidation of recently discovered mediators of angiogenesis.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


TUESDAY, JANUARY 6

15:00—19:30
Registration

Lower Atrium
18:30—19:30
Refreshments

Lower Atrium
19:30—20:30
Keynote Lecture
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Lee M. Ellis, University of Texas MD Anderson Cancer Center, USA

* Luisa Iruela-Arispe, University of California, Los Angeles, USA

Peter F. Carmeliet, University of Leuven, VIB, Belgium
Angiogenesis in Cancer


WEDNESDAY, JANUARY 7

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:00
Current Clinical Status of Anti-Angiogenic Therapy for Cancer
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Lee M. Ellis, University of Texas MD Anderson Cancer Center, USA
Anti-VEGF Therapy: Successes and Failures in the Clinic

Axel Grothey, Mayo Clinic College of Medicine, USA
Clinical Toxicities of Anti-VEGF Therapy - Focus on Bevacizumab

John V. Heymach, University of Texas MD Anderson Cancer Center, USA
Circulating Endothelial Precursors as Surrogate Markers of Activity of Anti-VEGF Therapy

Emile E. Voest, University Medical Center Utrecht, Netherlands
Short Talk: Kinetics of Endothelial (Progenitor) Cell Release from the Bone Marrow in Patients Receiving Chemotherapy Predicts Response and Survival

Mark A. Rosen, University of Pennsylvania, USA
Non-Invasive Imaging of the Tumor Vascular Phenotype in Humans Undergoing Anti-Vascular and Anti-Angiogenic Therapies

09:20—09:40
Coffee Break

Lower Atrium
11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Jefferson/Madison
13:00—22:00
Poster Viewing

Jefferson/Madison
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Abnormalities of the Tumor Microvascular Network
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Luisa Iruela-Arispe, University of California, Los Angeles, USA

Laura E. Benjamin, ImClone Systems, USA
Akt Signaling in the Tumor Microenvironment

David A. Cheresh, University of California, San Diego, USA
A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation

Ombretta Salvucci, NCI, National Institutes of Health, USA
Short Talk: Requirement for EphrinB Activation in Mural Cells Association with Endothelial Cells during New Vessel Formation

Robert S. Kerbel, Sunnybrook Research Institute, Canada
Rapid Systemic Induction of Proangiogenic/Vasculogenic Factors by Chemotherapy or Antiangiogenic Drugs: Implications for Tumor Progression and Response to Therapy

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
19:30—22:00
Poster Session 1

Jefferson/Madison

THURSDAY, JANUARY 8

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:00
Tumor Angiogenesis, Inflammation and the Microenvironment
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Laura E. Benjamin, ImClone Systems, USA

Luisa Iruela-Arispe, University of California, Los Angeles, USA
Intracrine VEGF Signaling and Tumor Growth

Raymond N. DuBois, Arizona State University, USA
Inflammatory Mediators and Tumor Progression

Kristian Pietras, Lund University, Sweden
Exploring New Strategies to Target the Pro-Angiogenic Tumor Stroma

Calvin Kuo, Stanford University, USA
Short Talk: Angiogenic Phenotypes of the Egfl7 Locus are Attributable to the Embedded MicroRNA miR-126

J. Silvio Gutkind, University of California, San Diego, USA
Semaphorin-Regulated Signaling Networks and Tumor-Induced Angiogenesis

09:20—09:40
Coffee Break

Lower Atrium
11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Jefferson/Madison
13:00—22:00
Poster Viewing

Jefferson/Madison
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Vascular Stem and Progenitor Cells
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Robert S. Kerbel, Sunnybrook Research Institute, Canada

Richard J. Gilbertson, University of Cambridge, UK
The Perivascular Niche for Tumor Stem Cells

Robert Benezra, Memorial Sloan-Kettering Cancer Center, USA
Id Proteins and Vascular Mobilization

Avner Adini, Children's Hospital, Boston, USA
Short Talk: Prominin-1/CD133, is More than a Marker of Premature Hematopoietic Cells

M. Celeste Simon, University of Pennsylvania, USA
Hypoxia, HIF and Stem Cells

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
19:30—22:00
Poster Session 2

Jefferson/Madison

FRIDAY, JANUARY 9

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:00
Tumor Lymphangiogenesis
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Robert Benezra, Memorial Sloan-Kettering Cancer Center, USA

Barbara H. Garmy-Susini, University of California, San Diego, USA
Central Requirement for Integrin Signaling in Lymphangiogenesis and Metastasis

Michael J. Detmar, ETH - Z├╝rich, Switzerland
Molecular Control of Lymphangiogenesis

Peter Friedl, NCMLS, Radboud University Nijmegen Medical Centre, Netherlands
Collective Invasion and Radioresistance at the Tumor-Vessel Interface

Yusuke Mizukami, Asahikawa Medical College, Japan
Short Talk: Hedgehog Signaling Regulates Angiogenesis in Pancreatic Cancer

Tuomas Tammela, Koch Institute for Integrative Cancer Research at MIT, USA
VEGFR-3 Pathway as a Target to Inhibit Angiogenesis, Lymphangiogenesis and Tumor Metastasis

09:20—09:40
Coffee Break

Lower Atrium
11:00—17:00
On Own for Lunch

11:00—13:00
Poster Setup

Jefferson/Madison
13:00—22:00
Poster Viewing

Jefferson/Madison
16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Imaging Angiogenesis: Histopathologic and Non-Invasive Imaging of Live Animals
Meeting has ended...abstracts no longer viewable online.

Gallatin
Jan E. Schnitzer, Proteogenomics Research Institute for Systems Medicine (PRISM), USA
Proteomic Imaging of Tumor Microenvironment and Angiogenesis in vivo for Enhancing Targeted Therapies

Lily Wu, University of California, Los Angeles, USA
Functional Molecular Imaging of Prostate Cancer Lymphatic Metastasis

Myunghwan Choi, Korea Advanced Institute of Science and Technology, South Korea
Short Talk: Dynamic Fluorescence Imaging for Multiparametric Measurement of Tumor Vasculature

* Donald M. McDonald, University of California, San Francisco, USA
Imaging of Cellular Actions of Angiogenesis Inhibitors

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
19:30—22:00
Poster Session 3

Jefferson/Madison

SATURDAY, JANUARY 10

07:00—08:00
Breakfast

Jefferson/Madison
08:00—11:00
Emerging Targets and Endothelial Cell Biology
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Gregory D. Plowman, Eli Lilly and Company, USA

Richard O. Hynes, Massachusetts Institute of Technology, USA
Cell-Matrix Interactions in Vascular Development

Hellmut G. Augustin, DKFZ & Heidelberg University, Germany
Angiopoietins and Tie-2

Beverly A. Teicher, Genzyme Corporation, USA
Endosialin/CD248: The Evolution of a Target

Napoleone Ferrara, University of California, San Diego, USA
Myeloid Dependent Tumor Angiogenesis and Bv8

09:20—09:40
Coffee Break

Lower Atrium
11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Lower Atrium
17:00—19:00
Notch Signaling
Meeting has ended...abstracts no longer viewable online.

Gallatin
* Jan K. Kitajewski, Columbia University, USA
Notch Signaling in Tumor Angiogenesis

Nicholas W. Gale, Regeneron Pharmaceuticals Inc., USA
Targeting Tumor Microvasculature via the VEGF and Delta/Notch Pathways

Ji-Liang Li, Weatherall Institute of Molecular Medicine, University of Oxford, UK
Short Talk: DLL4 Enhances Tumour Growth and Mediates Tumour Resistance to Anti-VEGF Therapy in vivo

Gregory D. Plowman, Eli Lilly and Company, USA
Contrasting Roles of VEGF and DLL4 in Vascular Biology

19:00—20:00
Social Hour with Lite Bites

Jefferson/Madison
20:00—23:00
Entertainment

Jefferson/Madison

SUNDAY, JANUARY 11

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA135834-01




We gratefully acknowledge additional support for this conference from:

Genentech BioOncology

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Genzyme Corporation


Regeneron Pharmaceuticals, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Cell Press

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676